S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Viking Therapeutics (VKTX) Competitors

$63.42
-1.25 (-1.93%)
(As of 04/19/2024 ET)

VKTX vs. CERE, ITCI, CYTK, JAZZ, ASND, ELAN, APLS, IONS, LEGN, and BPMC

Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), Apellis Pharmaceuticals (APLS), Ionis Pharmaceuticals (IONS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.

Viking Therapeutics vs.

Cerevel Therapeutics (NASDAQ:CERE) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.

Cerevel Therapeutics' return on equity of -27.78% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cerevel TherapeuticsN/A -100.14% -44.51%
Viking Therapeutics N/A -27.78%-26.37%

In the previous week, Viking Therapeutics had 5 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 12 mentions for Viking Therapeutics and 7 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of 0.68 beat Viking Therapeutics' score of 0.56 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cerevel Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viking Therapeutics
5 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerevel TherapeuticsN/AN/A-$432.84M-$2.50-16.88
Viking TherapeuticsN/AN/A-$85.89M-$0.92-68.93

Cerevel Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cerevel Therapeutics currently has a consensus price target of $41.40, indicating a potential downside of 1.92%. Viking Therapeutics has a consensus price target of $112.25, indicating a potential upside of 76.99%. Given Cerevel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cerevel Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerevel Therapeutics
0 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Viking Therapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00

Viking Therapeutics received 441 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Viking Therapeutics an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.

CompanyUnderperformOutperform
Cerevel TherapeuticsOutperform Votes
155
66.52%
Underperform Votes
78
33.48%
Viking TherapeuticsOutperform Votes
596
80.00%
Underperform Votes
149
20.00%

Summary

Viking Therapeutics beats Cerevel Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VKTX vs. The Competition

MetricViking TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.99B$6.54B$4.84B$7.31B
Dividend YieldN/A3.13%2.93%3.99%
P/E Ratio-68.938.78193.2615.96
Price / SalesN/A301.882,460.4981.65
Price / CashN/A28.6246.5034.42
Price / Book18.225.434.544.15
Net Income-$85.89M$146.64M$103.98M$214.00M
7 Day Performance-7.58%-6.86%-4.48%-3.52%
1 Month Performance-10.73%-9.99%-6.64%-5.50%
1 Year Performance209.97%-6.06%7.72%3.52%

Viking Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERE
Cerevel Therapeutics
0.1677 of 5 stars
$41.31
-0.9%
$41.40
+0.2%
+60.8%$7.50BN/A-16.52334News Coverage
ITCI
Intra-Cellular Therapies
4.0298 of 5 stars
$79.84
+23.3%
$81.42
+2.0%
+19.0%$7.73B$464.37M-54.68610Analyst Report
News Coverage
High Trading Volume
CYTK
Cytokinetics
3.9004 of 5 stars
$69.00
+1.5%
$79.33
+15.0%
+84.6%$7.22B$7.53M-12.66423Positive News
JAZZ
Jazz Pharmaceuticals
4.8685 of 5 stars
$108.90
-1.8%
$195.08
+79.1%
-24.1%$6.86B$3.83B17.792,800
ASND
Ascendis Pharma A/S
1.6316 of 5 stars
$141.50
-2.6%
$173.25
+22.4%
+68.8%$8.24B$288.08M-15.30879Upcoming Earnings
Analyst Report
ELAN
Elanco Animal Health
3.7233 of 5 stars
$13.65
-1.6%
$16.71
+22.5%
+33.1%$6.73B$4.42B-5.469,300Positive News
APLS
Apellis Pharmaceuticals
4.4698 of 5 stars
$51.82
+0.6%
$78.60
+51.7%
-42.3%$6.25B$396.59M-11.57702Analyst Report
Analyst Revision
News Coverage
IONS
Ionis Pharmaceuticals
4.1679 of 5 stars
$41.54
0.0%
$56.08
+35.0%
+12.6%$6.05B$788M-16.23927Insider Selling
Analyst Revision
LEGN
Legend Biotech
2.4071 of 5 stars
$50.12
-3.1%
$82.70
+65.0%
-27.5%$9.12B$285.14M-33.861,800Analyst Report
Analyst Revision
News Coverage
High Trading Volume
BPMC
Blueprint Medicines
0.8218 of 5 stars
$86.09
+1.1%
$85.43
-0.8%
+80.3%$5.27B$249.38M-10.30655Positive News

Related Companies and Tools

This page (NASDAQ:VKTX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners